HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Accepted manuscript (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Montemurro, F. Articles by Aglietta, M. PubMed PubMed Citation Articles by Montemurro, F. Articles by Aglietta, M.

F Montemurro, Medical Oncology, Institute for Cancer Research and Treatment (IRCC), Candiolo, 10060, Italy
M Aglietta, Medical Oncology, Institute for Cancer Research and Treatment (IRCC), Candiolo, Italy

Correspondence: Filippo Montemurro, Email: filippo.montemurro{at}ircc.it

Abstract

Current adjuvant treatments for operable breast cancer include chemotherapy, endocrine therapy in hormone-receptor positive tumors, and trastuzumab for HER2-positive tumors. Metanalyses of randomized trials show that in patients with hormone receptor positive breast cancer the effects of endocrine therapy and chemotherapy on survival are non-mutually exclusive. Most of these patients are therefore considered candidates to combined treatment. Recently, however, the endocrine-responsiveness of tumors has been redefined on clinical, histopathological and molecular bases. An emerging concept is that as endocrine-responsiveness increases, chemoresponsiveness decreases. In the adjuvant setting therapeutic choices are often based on small projected improvements clinical outcomes. As a consequence, the role of chemotherapy and traditional management algorithms in patients with hormone-receptor positive are being challenged. This review will address the current controversy regarding the role of adjuvant chemotherapy, including the newer anthracycline and taxanes-based programs, in these patients.